Press Release TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Press Release HUHUTECH International Group Inc. Announces First Half of Fiscal Year 2025 Financial Results
Press Release NIBS Assumes Management of the Sustainable Facilities Tool to Power the Future of Federal Building Innovation
Press Release Skywork.ai Redefines Enterprise Productivity with DeepResearch AI Agents Built for Real-World Industry Demands
